EGFR and non-small cell lung carcinoma: For example, as mentioned before, the FDA approved Cobas EGFR Mutation test v2 (Roche Molecular System, Inc) aims at distinguishing NSCLC patients that will benefit from EGFR-targeted therapy [16] and the Guardan360 (Guardant Health) examines a 73-gene panel in cfDNA to help NSCLC treatment selection.